Naringin Protects against Tau Hyperphosphorylation in Aβ_25–35-Injured PC12 Cells through Modulation of ER, PI3K/AKT, and GSK-3β Signaling Pathways

Figure 6

Effect of naringin on the ER pathway in the context of Aβ_25–35-induced injury. (a) Relative qRT-PCR was implemented to monitor the expression of ER mRNA. (b) Immunoblots were used to assess levels of ERβ, p-AKT (Ser473, Thr308), AKT, p-GSK-3β (Ser9), GSK-3β, p-Tau (Thr231, Ser396), and Tau proteins. (c) Quantitative analysis of ERβ/β-actin protein levels. (d) Quantitative analysis of p-AKT (Ser473)/AKT protein levels. (e) Quantitative analysis of p-AKT (Thr308)/AKT protein levels. (f) Quantitative analysis of p-GSK-3β (Ser9)/GSK-3β protein levels. (g) Quantitative analysis of p-Tau (Thr231)/Tau protein levels. (h) Quantitative analysis of p-Tau (Ser396)/Tau protein levels. Data are expressed as mean ± SD (). Compared with untreated cells, ** ; compared with Aβ_25–35-treated cells, ^##; compared with the treatment group, ^▲▲.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)